A detailed history of Geode Capital Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,738,646 shares of CYTK stock, worth $141 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,738,646
Previous 2,247,165 21.87%
Holding current value
$141 Million
Previous $158 Million 5.82%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$47.86 - $75.05 $23.5 Million - $36.9 Million
491,481 Added 21.87%
2,738,646 $148 Million
Q1 2024

May 13, 2024

BUY
$63.75 - $108.06 $10 Million - $17 Million
157,040 Added 7.51%
2,247,165 $158 Million
Q4 2023

Feb 13, 2024

BUY
$26.88 - $83.49 $3 Million - $9.33 Million
111,760 Added 5.65%
2,090,125 $175 Million
Q3 2023

Nov 13, 2023

BUY
$29.46 - $36.61 $2.04 Million - $2.53 Million
69,134 Added 3.62%
1,978,365 $58.3 Million
Q2 2023

Aug 11, 2023

BUY
$32.62 - $40.75 $5.69 Million - $7.11 Million
174,535 Added 10.06%
1,909,231 $62.3 Million
Q1 2023

May 15, 2023

BUY
$33.36 - $45.71 $2.56 Million - $3.51 Million
76,846 Added 4.64%
1,734,696 $61 Million
Q4 2022

Feb 13, 2023

BUY
$35.77 - $51.11 $2.37 Million - $3.39 Million
66,392 Added 4.17%
1,657,850 $76 Million
Q3 2022

Nov 14, 2022

BUY
$38.54 - $54.52 $4.16 Million - $5.88 Million
107,936 Added 7.28%
1,591,458 $77.1 Million
Q2 2022

Aug 12, 2022

BUY
$33.93 - $48.92 $393,961 - $568,010
11,611 Added 0.79%
1,483,522 $58.3 Million
Q1 2022

May 13, 2022

BUY
$29.74 - $46.0 $1.29 Million - $1.99 Million
43,289 Added 3.03%
1,471,911 $54.2 Million
Q4 2021

Feb 11, 2022

BUY
$34.35 - $46.38 $1.05 Million - $1.42 Million
30,574 Added 2.19%
1,428,622 $65.1 Million
Q3 2021

Nov 12, 2021

BUY
$18.54 - $35.74 $3.48 Million - $6.71 Million
187,626 Added 15.5%
1,398,048 $50 Million
Q2 2021

Aug 13, 2021

BUY
$19.79 - $26.99 $1.03 Million - $1.41 Million
52,294 Added 4.52%
1,210,422 $24 Million
Q1 2021

May 12, 2021

BUY
$18.57 - $25.68 $1.9 Million - $2.63 Million
102,567 Added 9.72%
1,158,128 $26.9 Million
Q4 2020

Feb 12, 2021

BUY
$15.26 - $28.61 $802,904 - $1.51 Million
52,615 Added 5.25%
1,055,561 $21.9 Million
Q3 2020

Nov 13, 2020

BUY
$20.58 - $28.96 $2.71 Million - $3.82 Million
131,880 Added 15.14%
1,002,946 $21.7 Million
Q2 2020

Aug 13, 2020

BUY
$11.15 - $24.64 $148,406 - $327,958
13,310 Added 1.55%
871,066 $20.5 Million
Q1 2020

May 14, 2020

BUY
$8.75 - $16.3 $505,610 - $941,879
57,784 Added 7.22%
857,756 $10.1 Million
Q4 2019

Feb 13, 2020

BUY
$7.95 - $11.84 $66,008 - $98,307
8,303 Added 1.05%
799,972 $8.49 Million
Q3 2019

Nov 12, 2019

BUY
$10.82 - $14.25 $406,139 - $534,888
37,536 Added 4.98%
791,669 $9.01 Million
Q2 2019

Aug 14, 2019

BUY
$7.95 - $11.25 $659,834 - $933,727
82,998 Added 12.37%
754,133 $8.48 Million
Q1 2019

May 14, 2019

BUY
$5.95 - $10.19 $509,272 - $872,182
85,592 Added 14.62%
671,135 $5.43 Million
Q4 2018

Feb 13, 2019

BUY
$5.91 - $9.29 $419,338 - $659,162
70,954 Added 13.79%
585,543 $3.7 Million
Q3 2018

Nov 13, 2018

BUY
$6.4 - $9.85 $116,089 - $178,669
18,139 Added 3.65%
514,589 $5.07 Million
Q2 2018

Aug 14, 2018

BUY
$6.9 - $9.9 $430,077 - $617,067
62,330 Added 14.36%
496,450 $4.12 Million
Q1 2018

May 15, 2018

BUY
$7.2 - $10.05 $40,118 - $55,998
5,572 Added 1.3%
434,120 $3.13 Million
Q4 2017

Feb 13, 2018

BUY
$7.25 - $15.65 $49,394 - $106,623
6,813 Added 1.62%
428,548 $3.49 Million
Q3 2017

Nov 14, 2017

SELL
$12.0 - $15.0 $318,492 - $398,115
-26,541 Reduced 5.92%
421,735 $6.12 Million
Q2 2017

Aug 14, 2017

BUY
N/A
448,276
448,276 $5.42 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.85B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.